5 Key Takeaways

• 1

  The Automated Retinal Disease Assessment (ARDA) AI model was deployed across 45 clinics in India to screen for diabetic retinopathy and diabetic macular edema.

• 2

  ARDA demonstrated a sensitivity of 97% and specificity of 96.4% for severe plus diabetic retinopathy in a large-scale real-world evaluation.

• 3

  Over 600,000 patients were screened using ARDA between 2019 and 2023, with a positive predictive value of approximately 50% for clinically significant conditions.

• 4

  Nontechnical factors such as staff training and patient education were crucial for the successful deployment of the ARDA system.

• 5

  The study authors emphasized the importance of monitoring and publishing clinical performance for AI algorithms to ensure patient safety.